Y Intercept Hong Kong Ltd Makes New $91,000 Investment in Actinium Pharmaceuticals, Inc. $ATNM

Y Intercept Hong Kong Ltd purchased a new position in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 64,909 shares of the company’s stock, valued at approximately $91,000. Y Intercept Hong Kong Ltd owned approximately 0.21% of Actinium Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ATNM. Gagnon Securities LLC acquired a new position in Actinium Pharmaceuticals in the first quarter worth approximately $365,000. Invesco Ltd. grew its position in Actinium Pharmaceuticals by 1,135.9% in the first quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock worth $247,000 after acquiring an additional 141,130 shares in the last quarter. Nuveen LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $239,000. Charles Schwab Investment Management Inc. increased its stake in shares of Actinium Pharmaceuticals by 35.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 97,604 shares of the company’s stock worth $157,000 after purchasing an additional 25,511 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Trading Down 4.5%

ATNM stock opened at $1.26 on Monday. The firm has a market cap of $39.31 million, a PE ratio of -0.91 and a beta of -0.25. Actinium Pharmaceuticals, Inc. has a 1 year low of $1.03 and a 1 year high of $2.41. The company has a fifty day simple moving average of $1.55 and a 200 day simple moving average of $1.58.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).